Voltari Corporation, together with its subsidiaries, provides relevance-driven mobile advertising, mobile marketing, mobile merchandising, and predictive analytics solutions for mobile operators, brands, and agencies. The company offers Voltari-Connect, a data management platform that provides targeting capabilities to identify and attract mobile audiences based on customer preferences and interests. It also offers solution consulting services comprising defining mobile trends, analyzing effectiveness of existing solutions, and recommending programs and solutions to enhance the mobile data subscriber experience. The company's solutions enable advertising agencies, consumer brands, and enterprises, and mobile operators to deliver mobile optimized, consumer-centric experiences that promote interaction, content consumption, and commerce across the mobile ecosystem. Voltari Corporation was founded in 2001 and is headquartered in New York, New York.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. The company has agreements with CVie Therapeutics to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in China, Hong Kong, and Macau; and Novellus Biopharma AG to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. It also has agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in various territories worldwide. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.
Energy Recovery, Inc. designs, develops, and manufactures energy recovery devices (ERDs) to transform untapped energy into reusable energy from industrial fluid flows and pressure cycles. The company's products include PX ERDs and turbochargers for water desalination; AT and Halo turbochargers for low-pressure brackish and high-pressure seawater reverse osmosis systems; Pressure Exchanger energy recovery devices and turbochargers; and high-pressure pumps. It also offers IsoBoost energy recovery systems comprising turbines and industrial pumps; and lsoGen systems that enable oil and gas operators to capture hydraulic energy and generate electricity from high-pressure fluid flows. In addition, the company provides engineering, technical support, and training services; and preventive maintenance and support services, as well as reinstallation services. It serves engineering, procurement, and construction firms that design and build large desalination plants; original equipment manufacturers; and oil companies, and exploration and production companies. The company markets its products directly to customers through its sales organization, as well as through authorized independent sales agents in the United States and internationally. Energy Recovery, Inc. was founded in 1992 and is headquartered in San Leandro, California.
Immune Design Corp., a clinical-stage immunotherapy company, focuses on the development of novel immune-based therapies based on its DCVex and GLAAS discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. The company was founded in 2008 and is headquartered in Seattle, Washington.
EnerJex Resources, Inc., an independent energy company, acquires, develops, exploits, and produces crude oil and natural gas in the United States. It owns oil and gas leases covering approximately 100,000 acres in various prolific hydrocarbon basins located in Colorado, Kansas, Nebraska, and Texas. As of December 31, 2013, its total proved reserves consisted of 5.8 million barrels of oil equivalent. EnerJex Resources, Inc. is headquartered in San Antonio, Texas.
Oi S.A., through its subsidiaries, provides integrated telecommunication services for residential customers, companies, and governmental agencies in Brazil. It operates in three segments: Fixed-Line and Data Transmission Services, Mobile Services, and Other Services. The company offers fixed-line voice services, such as installation, monthly subscription, metered services, collect calls, and supplemental local services; domestic and international long-distance services; broadband Internet access services; subscription television services; and bundled services, as well as owns and operates public telephones. It also provides post-paid and pre-paid mobile voice and mobile data communications services; mobile long-distance services; value-added services, which include voice, text, and data applications consisting of voicemail, caller ID, personalization, text messaging subscription, chat, mobile television, and location-based services and applications; digital trunk services; and advanced voice services and voice portals, as well as leases digital and analog lines for use in private networks. Further, it provides mobile plans to small and medium-sized enterprises; data transmission services comprising interconnection between local area networks, videoconferencing, video/image transmission, and multimedia applications; information technology infrastructure services; data center services; managed services for mobile devices; interconnection and network usage charges, and traffic transportation services for other telecommunications providers; and ISP services, as well as operates an Internet portal and a call center. As of December 31, 2013, it had approximately 655,400 public telephones; and 11.6 million fixed lines in service in Region I and 6.7 million fixed lines in service in Region II. The company was formerly known as Brasil Telecom S.A. and changed its name to Oi S.A. in February 2012. Oi S.A. was founded in 1963 and is headquartered in Rio de Janeiro, Brazil.
Lightbridge Corporation, a nuclear fuel technology company, through its subsidiaries, participates in the nuclear power industry in the United States and internationally. It operates two segments, Technology and Consulting. The Technology segment engages in the design and development of proprietary nuclear fuels. Its primary fuel product lines include all-uranium seed and blanket fuel for existing plants; all-metal fuel for new build reactors; and thorium-based seed and blanket fuel for both existing and new build reactors. The Consulting segment provides nuclear power consulting and strategic advisory services to commercial and governmental entities. It offers integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, and regulatory affairs. The company was formerly known as Thorium Power, Ltd. and changed its name to Lightbridge Corporation in September 2009. Lightbridge Corporation was founded in 1992 and is based in McLean, Virginia.
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L'Oreal. The company was founded in 2007 and is headquartered in San Diego, California.
Trillium Therapeutics Inc., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.